Advanced search
Publication Cover
Current Medical Research and Opinion Volume 39, 2023 - Issue 11
Submit an article Journal homepage
953
Views
0
CrossRef citations to date
0
Altmetric
Diabetes

The incremental cost of non-alcoholic steatohepatitis and type 2 diabetes in the United States using real-world data

Jesse Fishmana Madrigal Pharmaceuticals, West Conshohocken, PA, USACorrespondence[email protected]
View further author information
,
Elliot B. Tapperb University of Michigan, Ann Arbor, MI, USAView further author information
,
Stephen Dodgea Madrigal Pharmaceuticals, West Conshohocken, PA, USAView further author information
,
Keith Millera Madrigal Pharmaceuticals, West Conshohocken, PA, USAView further author information
,
Dave Lewandowskic Veradigm Life Sciences, Chicago, IL, USAView further author information
,
Alina Bogdanovc Veradigm Life Sciences, Chicago, IL, USAView further author information
&
Machaon Bonafedec Veradigm Life Sciences, Chicago, IL, USAView further author information
 show all
Pages 1425-1429 | Received 17 Aug 2023, Accepted 21 Sep 2023, Published online: 04 Oct 2023

References

  • Sheka AC, Adeyi O, Thompson J, et al. Nonalcoholic steatohepatitis: a review. JAMA. 2020;323(12):1175–1183. doi:10.1001/jama.2020.2298.
  • Gastaldelli A, Cusi K. From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options. JHEP Rep. 2019;1(4):312–328. doi:10.1016/j.jhepr.2019.07.002.
  • Khan MAB, Hashim MJ, King JK, et al. Epidemiology of type 2 diabetes – global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020;10(1):107–111. doi:10.2991/jegh.k.191028.001.
  • Estes C, Razavi H, Loomba R, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67(1):123–133. doi:10.1002/hep.29466.
  • Park J, Bigman E, Zhang P. Productivity loss and medical costs associated with type 2 diabetes among employees aged 18-64 years with large Employer-Sponsored insurance. Diabetes Care. 2022;45(11):2553–2560. doi:10.2337/dc22-0445.
  • Wong RJ, Kachru N, Martinez DJ, et al. Real-world comorbidity burden, health care utilization, and costs of nonalcoholic steatohepatitis patients with advanced liver diseases. J Clin Gastroenterol. 2021;55(10):891–902. doi:10.1097/MCG.0000000000001409.
  • Younossi ZM, Tampi RP, Racila A, et al. Economic and clinical burden of nonalcoholic steatohepatitis in patients with type 2 diabetes in the U.S. Diabetes Care. 2020;43(2):283–289. doi:10.2337/dc19-1113.
  • Boikos C, Imran M, De Lusignan S, et al. Integrating electronic medical records and claims data for influenza vaccine research. Vaccines. 2022;10(5):727. doi:10.3390/vaccines10050727.
  • Tapper EB, Bonafede M, Fishman J, et al. Healthcare resource utilization and costs of care in the United States for patients with non-alcoholic steatohepatitis. J Med Econ. 2023;26(1):348–356.
  • Motheral B, Brooks J, Clark MA, et al. A checklist for retrospective database studies—report of the ISPOR task force on retrospective databases. Value Health. 2003;6(2):90–97. doi:10.1046/j.1524-4733.2003.00242.x.
  • Tapper E, Fishman J, Dodge S, et al. A higher fibrosis-4 (FIB-4) score is associated with higher healthcare costs and hospitalizations in patients with non-alcoholic steatohepatitis (NASH). J Hepatol. 2022;77:S167. https://www.journal-of-hepatology.eu/article/S0168-8278(22)00714-0/fulltext#relatedArticles. doi:10.1016/S0168-8278(22)00714-0.
  • Quan H, Li B, Couris CM, et al. Updating and validating the charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–682. doi:10.1093/aje/kwq433.
  • Glasheen WP, Renda A, Dong Y. Diabetes complications severity index (DCSI)—update and ICD-10 translation. J Diabetes Complications. 2017;31(6):1007–1013. doi:10.1016/j.jdiacomp.2017.02.018.
  • Witkowski M, Moreno SI, Fernandes J, et al. The economic burden of non-alcoholic steatohepatitis: a systematic review. Pharmacoeconomics. 2022;40(8):751–776. doi:10.1007/s40273-022-01140-y.
  • Gordon SC, Fraysse J, Li S, et al. Disease severity is associated with higher healthcare utilization in nonalcoholic steatohepatitis medicare patients. Am J Gastroenterol. 2020;115(4):562–574. doi:10.14309/ajg.0000000000000484.
  • Hagström H, Adams LA, Allen AM, et al. Administrative coding in electronic health care record-based research of NAFLD: an expert panel consensus statement. Hepatology. 2021;74(1):474–482. doi:10.1002/hep.31726.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.